These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32307496)

  • 21. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells.
    Garufi A; Trisciuoglio D; Porru M; Leonetti C; Stoppacciaro A; D'Orazi V; Avantaggiati M; Crispini A; Pucci D; D'Orazi G
    J Exp Clin Cancer Res; 2013 Oct; 32(1):72. PubMed ID: 24220325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.
    Sankala H; Vaughan C; Wang J; Deb S; Graves PR
    Arch Biochem Biophys; 2011 Aug; 512(1):52-60. PubMed ID: 21621504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.
    Zhang Q; Bykov VJN; Wiman KG; Zawacka-Pankau J
    Cell Death Dis; 2018 May; 9(5):439. PubMed ID: 29670092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
    Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
    Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity.
    Hibino E; Tenno T; Hiroaki H
    Front Mol Biosci; 2022; 9():869851. PubMed ID: 35558561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.
    Kovachev PS; Banerjee D; Rangel LP; Eriksson J; Pedrote MM; Martins-Dinis MMDC; Edwards K; Cordeiro Y; Silva JL; Sanyal S
    J Biol Chem; 2017 Jun; 292(22):9345-9357. PubMed ID: 28420731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thermodynamic stability of wild-type and mutant p53 core domain.
    Bullock AN; Henckel J; DeDecker BS; Johnson CM; Nikolova PV; Proctor MR; Lane DP; Fersht AR
    Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14338-42. PubMed ID: 9405613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the disordered conformational ensembles of the p53 transactivation domain by cancer-associated mutations.
    Ganguly D; Chen J
    PLoS Comput Biol; 2015 Apr; 11(4):e1004247. PubMed ID: 25897952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.
    Calhoun S; Daggett V
    Biochemistry; 2011 Jun; 50(23):5345-53. PubMed ID: 21561095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations.
    Koulgi S; Achalere A; Sonavane U; Joshi R
    PLoS One; 2015; 10(11):e0143065. PubMed ID: 26579714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
    Joerger AC; Ang HC; Veprintsev DB; Blair CM; Fersht AR
    J Biol Chem; 2005 Apr; 280(16):16030-7. PubMed ID: 15703170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants.
    Demir Ö; Baronio R; Salehi F; Wassman CD; Hall L; Hatfield GW; Chamberlin R; Kaiser P; Lathrop RH; Amaro RE
    PLoS Comput Biol; 2011 Oct; 7(10):e1002238. PubMed ID: 22028641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
    Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
    Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Oncological Effect of Mutant p53 on the Metastatic Phenotype of Gastric Cancer Cells.
    Kitagawa H; Hiraki M; Namba T; Baba K; Miyake S; Ito K; Tanaka T; Noshiro H
    Anticancer Res; 2023 Nov; 43(11):4887-4895. PubMed ID: 37909947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.
    Samassekou O; Bastien N; Lichtensztejn D; Yan J; Mai S; Drouin R
    Genes Chromosomes Cancer; 2014 Nov; 53(11):934-50. PubMed ID: 25059482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The p53 core domain is a molten globule at low pH: functional implications of a partially unfolded structure.
    Bom AP; Freitas MS; Moreira FS; Ferraz D; Sanches D; Gomes AM; Valente AP; Cordeiro Y; Silva JL
    J Biol Chem; 2010 Jan; 285(4):2857-66. PubMed ID: 19933157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
    Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity.
    Thompson LR; Oliveira TG; Hermann ER; Chowanadisai W; Clarke SL; Montgomery MR
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.